Key result
The novel peptidomimetic aldehyde compound 10d potently inhibited the replication of the human norovirus GI.1 replicon in vitro with an EC50 of 0.012 µM.
Why the study?
Human noroviruses are the most common cause of viral gastroenteritis resulting annually in ~219,000 deaths, yet no antivirals or vaccines are available.
Effect estimate: EC50 0.012 µM
Compound 10d, a novel peptidomimetic aldehyde targeting the viral protease, demonstrates potent anti-norovirus activity in vitro and in vivo, representing a promising candidate for norovirus treatment.
Supports further preclinical evaluation of 10d; leaves open translation to human norovirus therapy.
Human noroviruses (HuNoVs) are the most common cause of viral gastroenteritis resulting annually in ~219,000 deaths and a societal cost of ~USD 60 billion, and no antivirals or vaccines are available. Here, we assess the anti-norovirus activity of new peptidomimetic aldehydes related to the protease inhibitor rupintrivir. The early hit compound 4 inhibited the replication of murine norovirus (MNV) and the HuNoV GI.1 replicon in vitro (EC50 ~1 µM) and swiftly cleared the HuNoV GI.1 replicon from the cells. Compound 4 still inhibits the proteolytic activity. We selected a resistant GI.1 replicon, with a mutation (I109V) in a highly conserved region of the viral protease, conferring a low yield of resistance against compound 4 and rupintrivir. After testing new derivatives, compound 10d was the most potent (EC50 nanomolar range). Molecular docking indicated that the aldehyde group of compounds 4 and 10d bind with Cys139 in the HuNoV 3CL protease by a covalent linkage. Finally, compound 10d inhibited the replication of HuNoV GII.4 in infected zebrafish larvae, and PK studies in mice showed an adequate profile.
No takes yet. Share an insight, caveat, or question.
Dycke et al. (2021) studied Norovirus infection. Compound 10d (peptidomimetic aldehyde) vs. Untreated control / Rupintrivir was evaluated on Inhibition of human norovirus GI.1 replicon in vitro (EC50) (EC50 0.012 µM). The novel peptidomimetic aldehyde compound 10d potently inhibited the replication of the human norovirus GI.1 replicon in vitro with an EC50 of 0.012 µM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: